Leon Aarons
Leon Aarons | |
|---|---|
| Born | Australia |
| Alma mater | University of Calgary, University of Manchester |
| Occupation(s) | Chemist, pharmacometrician |
| Years active | 1976–present |
| Employer | University of Manchester |
| Known for | Pharmacodynamics, pharmacokinetics, pharmacometrics |
Leon Aarons is an Australian chemist with expertise in pharmacodynamics and pharmacokinetics. Since 1976, he has held a professorship in pharmacometrics at the University of Manchester in the United Kingdom. His research primarily aims to enhance pharmacological modeling, design clinical trials, and perform data analysis within the realm of population pharmacokinetics, all to support effective drug development. Between 1985 and 2010, Aarons was editor emeritus of the Journal of Pharmacokinetics and Pharmacodynamics and also served as an executive editor for the British Journal of Clinical Pharmacology.
Data modelling
Aarons’ investigations focus on elucidating how drugs and toxic substances influence human physiology. In 2009, he co-developed a model that integrates the kinetics of compounds with their biological effects, offering an alternative to the conventional dose-effect framework that directly correlates exposure with patient response. This work highlighted that drug action involves a sequential "chain of events" spanning molecular interactions to systemic outcomes, which may be therapeutic or harmful. The publication proposed a conceptual approach to advance pharmacodynamic and pharmacokinetic modeling by incorporating principles from systems biology, stressing collaborative efforts to create well-defined models applicable in clinical settings.
Design of scientific investigations
Aarons characterized pharmacokinetics (PK) as the study of processes linking drug administration to anticipated effects, focusing on drug concentration changes through absorption, distribution, metabolism, and excretion phases. He utilized optimal design theory to refine experimental strategies in PK research, underscoring the importance of balancing factors such as timing of measurements and sample size. For population-based PK studies, Aarons emphasized the necessity for experimental design methodologies tailored to non-linear population PK models. A subsequent co-authored article reviewed optimal design techniques for population PK and pharmacodynamic experiments, acknowledging practical limitations while forecasting increased adoption to enhance study efficiency.
Enterohepatic circulation
Aarons investigated the phenomenon of enterohepatic cycling (EHC), a process where drugs recirculate between the liver, bile ducts, and small intestine, influencing drug half-life and potential hepatic toxicity. His research team highlighted that comprehending EHC mechanisms is vital for determining if a drug’s in vitro characteristics affect its absorption in vivo. He also contributed to analyses involving the AUC, a crucial parameter reflecting drug exposure and clearance, which guided sampling strategies for medications undergoing enterohepatic recycling.
Drug-drug interactions
Drug−drug interactions (DDI) represent a significant source of adverse events with considerable clinical consequences. In 1981, Aarons recognized the elevated risk posed by polypharmacy and reviewed pharmacokinetic factors influencing drug disposition, advocating for comprehensive models that account for all interacting entities. In 2011, he co-authored a critique addressing limitations of the two-fold criterion used in DDI evaluation, recommending incorporation of broader datasets and variability considerations to minimize bias. A 2017 investigation involving Aarons examined differences in oral bioavailability between original and generic drug formulations, attributing observed variations to diminished intestinal enzyme CYP3A4 activity. This study emphasized how formulation changes can affect clinically relevant DDIs involving CYP3A substrates—an aspect often neglected during development. Earlier work from 2008 applied physiologically based pharmacokinetic modelling (PBPK) to assess CYP3A4 inhibition potential of a drug candidate; subsequent analyses validated this approach as a valuable tool for interaction assessment in drug development processes.